CLINICAL TRIAL / NCT04978428

Epidiolex in Obsessive Compulsive Disorder and Related Disorders

  • Interventional
  • Recruiting
  • NCT04978428

Contact Information

  • Eve Chesivoir

An Open-Label Trial of Epidiolex in the Treatment of Obsessive Compulsive Disorder and Related Disorders: Proof of Concept Study

The primary objective of the proposed study is to evaluate the safety and efficacy of Epidiolex (cannabidiol) in adults with obsessive compulsive and related disorders (OCRDs). Subjects will be treated in an open-label fashion with Epidiolex for two weeks.